0.9684

5.98% -0.0616

Akebia Therapeutics Inc (AKBA)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$1.03

Offen:

$1.03

24-Stunden-Volumen:

2.54M

Relative Volume:

0.42

Marktkapitalisierung:

$268.35M

Einnahmen:

$232.40M

Nettoeinkommen (Verlust:

$-20.51M

KGV:

-12.56

EPS:

-0.0771

Netto-Cashflow:

$60.04M

1W Leistung:

-1.21%

1M Leistung:

+6.43%

6M Leistung:

-28.26%

1J Leistung:

-67.72%

1-Tages-Spanne:

$0.9682

$1.049

1-Wochen-Bereich:

$0.9471

$1.049

52-Wochen-Spanne:

$0.814

$3.20

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Firmenname

Akebia Therapeutics Inc

Sektor

Healthcare (1086)

Branche

Drug Manufacturers - Specialty & Generic (87)

Telefon

617-871-2098

Adresse

245 FIRST STREET, CAMBRIDGE, MA

Mitarbeiter

194

Twitter

@akebiatx

Nächster Verdiensttermin

2026-08-06

Neueste SEC-Einreichungen

AKBA's Discussions on Twitter

Compare AKBA vs TAK, TEVA, HLN, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AKBA Akebia Therapeutics Inc	0.9684	285.42M	232.40M	-20.51M	60.04M	-0.0771
TAK Takeda Pharmaceutical Co Adr	18.25	58.50B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.64	42.84B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.22	40.68B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	73.28	30.40B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	503.54	21.36B	3.17B	1.29B	1.01B	27.09

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-06-04	Fortgesetzt	H.C. Wainwright	Buy
2025-04-28	Eingeleitet	Leerink Partners	Outperform
2025-04-01	Eingeleitet	Jefferies	Buy
2023-11-29	Fortgesetzt	BTIG Research	Buy
2023-08-28	Hochstufung	H.C. Wainwright	Neutral → Buy
2023-05-31	Hochstufung	Piper Sandler	Neutral → Overweight
2022-03-31	Herabstufung	H.C. Wainwright	Buy → Neutral
2022-03-31	Herabstufung	Mizuho	Buy → Neutral
2022-03-31	Herabstufung	Needham	Buy → Hold
2022-03-31	Herabstufung	Piper Sandler	Overweight → Neutral
2021-03-08	Eingeleitet	Cantor Fitzgerald	Overweight
2021-01-29	Herabstufung	JP Morgan	Neutral → Underweight
2019-11-14	Bestätigt	Needham	Buy
2019-08-06	Bestätigt	H.C. Wainwright	Buy
2019-07-11	Bestätigt	H.C. Wainwright	Buy
2019-05-02	Eingeleitet	JP Morgan	Overweight
2019-03-20	Eingeleitet	Citigroup	Neutral
2018-09-07	Fortgesetzt	Morgan Stanley	Equal-Weight
2018-08-10	Bestätigt	Needham	Buy
2018-06-06	Bestätigt	H.C. Wainwright	Buy
2017-12-19	Eingeleitet	Piper Jaffray	Overweight
2017-12-07	Eingeleitet	BTIG Research	Buy
2017-09-15	Eingeleitet	RBC Capital Mkts	Sector Perform
2017-07-10	Bestätigt	H.C. Wainwright	Buy
2017-04-27	Bestätigt	H.C. Wainwright	Buy
2017-04-27	Bestätigt	Needham	Buy
2016-12-27	Bestätigt	H.C. Wainwright	Buy
2016-12-20	Bestätigt	JMP Securities	Mkt Outperform
2016-11-15	Eingeleitet	Aegis Capital	Buy
2016-09-29	Eingeleitet	Brean Capital	Buy
2016-03-16	Bestätigt	Needham	Buy
2016-01-21	Eingeleitet	Credit Suisse	Neutral

Alle ansehen

Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten

Sep 08, 2026

AKBA Initiates Coverage On WestPark Capital -- Rating Set to Buy - GuruFocus

Sep 08, 2026

Akebia Therapeutics (NASDAQ:AKBA) Earns Buy Rating from Analysts at Westpark Capital - MarketBeat

Sep 08, 2026

Sep 03, 2026

BlackRock Inc. Buys Shares of 19,986,374 Akebia Therapeutics, Inc. $AKBA - MarketBeat

Sep 03, 2026

Sep 01, 2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView

Sep 01, 2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 01, 2026

Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston - marketscreener.com

Sep 01, 2026

Aug 29, 2026

Nantahala Capital Management LLC Takes Position in Akebia Therapeutics, Inc. $AKBA - MarketBeat

Aug 29, 2026

Aug 26, 2026

Akebia Therapeutics (NASDAQ:AKBA) Stock Price Passes Below 200-Day Moving AverageWhat's Next? - MarketBeat

Aug 26, 2026

Aug 22, 2026

Akebia (AKBA) Market: Slides 1.39% to $0.91 for the Current Session; Key Range: the Near-Term Reference Band Stretches From $0.86 to $0.96 on the DayRTH Profile - vinanet.vn

Aug 22, 2026

Aug 18, 2026

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of "Hold" by Analysts - MarketBeat

Aug 18, 2026

Akebia Therapeutics, Inc. Revenue Breakdown – NASDAQ:AKBA - TradingView

Aug 18, 2026

Aug 17, 2026

Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4 - Moomoo

Aug 17, 2026

Aug 15, 2026

AKBA Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates by 33.18%Return On Equity - vinanet.vn

Aug 15, 2026

AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits

Aug 15, 2026

Aug 10, 2026

Akebia Therapeutics CEO John P. Butler Exercises 350,000 Stock Options at $0.63 Each - Kalkine Media

Aug 10, 2026

Weekly Recap: Vafseo sales surge and ebribafusp Phase 2 trial start - TradingView

Aug 10, 2026